HAIFA, ISRAEL, Nov. 10, 2009--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that it will be presenting at the Clinical Trial Magnifier Conference, in Hong Kong. Chaya Mazouz, B.Sc., R.N., M.A., vice president of clinical and regulatory affairs at Pluristem, will deliver an oral presentation entitled “Communicating with Regulatory Authorities” at 1:35 p.m. Hong Kong time, Nov. 13, 2009. Ms. Mazouz will also co-chair a panel discussion on the development, negotiation and the principles of clinical trial agreements at 11:30 a.m. Hong Kong time, Nov. 15, 2009.
“Pluristem is a clinical stage company with trials both in the U.S. and Europe for its placental expanded cell therapy product for the treatment of critical limb ischemia, PLX-PAD,” said Ms. Mazouz. “Communicating with regulators world-wide is critical for Pluristem as we advance our programs, especially because of the novel nature of our placental cell therapy products.”
The Clinical Trial Magnifier Conference is a multidisciplinary forum for clinical research professionals, specifically addressing the issues and challenges faced daily by professionals in the field. In line with its mission to encourage continuous improvement of professional practices, this conference will make critical information available to participating professionals. The conference is a neutral, global, forum completely independent from the influence of any organization or authority.
About Pluristem
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.
See our product animation on YouTube: Animation, the content of which is not part of this press release.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
For more information visit our website at www.pluristem.com, the content of which is not part of this press release.
